After recent updates on targeting KRASG12C and HRAS, let’s not forget that there are plenty of other elements of the RAS pathway that can be considered, not least is upstream receptor kinases such as EGFR and sideways to SHP2.
What happens when those worlds collide?
Quite a bit it would seem.
If we want to seriously impact patient outcomes for the better then we need to explore rational combination approaches.
Here’s one way to do it…
Please note that this is an early target with not very many competitors, so there’s plenty that can happen here on multiple fronts!